Second IVIg Dose in Guillain-Barre syndrome patients with poor prognosis.
Completed
- Conditions
- Guillain-Barre syndrome
- Registration Number
- NL-OMON22921
- Lead Sponsor
- Erasmus MC Rotterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 176
Inclusion Criteria
To enter this GBS study:
1. Patients are diagnosed with GBS[30];
Exclusion Criteria
1. Age less than 6 years;
2. Patient known to have a severe allergic reaction to properly matched blood products or plasma products;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine whether a second IVIg dosage in GBS patients with a poor prognosis improve functional outcome after 4 weeks.
- Secondary Outcome Measures
Name Time Method